Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today that the Company has completed recruitment of its pivotal Phase 3 European/Canadian psoriasis trial (ESSENCE). As of July 20, 2007, the Company closed recruitment at 638 patients. The patient population is made up of 228 Canadian patients, 294 patients from Germany and 116 patients from ...
Sydney, Australia (ots/PRNewswire) - Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment-experienced HIV-positive patients, and made achieving an undetectable viral load a realistic goal ...
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
Basel, Switzerland (ots/PRNewswire) - - First Medicine Shown to Extend Survival of Previously Untreated Patients Beyond One Year Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the first-line use of Avastin in the ...
Oss, The Netherlands (ots/PRNewswire) - Organon, the human healthcare business unit of Akzo Nobel, announced today that the Marketing Authorization Application (MAA) for sugammadex has been accepted for review by the European Medicines Agency (EMEA). This novel selective relaxant binding agent (SRBA) is specifically designed to reverse the effects of the muscle ...
Evry, France (ots/PRNewswire) - In preparation for the application for the listing of its shares on Eurolist by Euronext, Novagali Pharma, an emerging ophthalmic pharmaceutical company, announces that its document de base was registered on July 18, 2007 by the Autorité des marchés financiers (AMF) under number ...
Bethesda, Maryland (ots/PRNewswire) - - Company Expects Four Antibodies in Clinical Development by End of 2007 - Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for the treatment of cancer, inflammatory and autoimmune diseases, announced today the promotion of Carsten Reinhardt, M.D. from Senior Vice President of Clinical ...
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV announced today that the European Medicines Agency (EMEA) has accepted for review a Marketing Authorization Application (MAA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia (NP), including ...
World Glaucoma Association (WGA)
Singapore (ots/PRNewswire) - Today, leading experts from the World Glaucoma Association (WGA) launched the group's first consensus on intraocular pressure (IOP). The panel recognized that elevated IOP is the leading risk factor for glaucoma progression and accurate measurement of IOP plays a key role in assessing glaucoma risk and disease management. The panel's ...
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company is the First Company in the World to Produce Recombinant Apo AI, a Next Generation Cardiovascular Therapy, Using Plants SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company, today announced it has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AI(Milano) (collectively referred to as Apo AI) ...
PDUFA date of 4th March 4, 2008 established Lugano (ots) - Helsinn's Top Management today announced that the supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting was accepted for filing by the United States Food and Drug Administration (FDA). Aloxi is approved by the FDA ...
Amsterdam (ots/PRNewswire) - - Deputy Mayor of Amsterdam Starts Next Phase of Avantium's Biofuels Research Program. During the visit of the Deputy Mayor of Amsterdam, Mr. Lodewijk Asscher, Avantium has announced that it is active in developing a novel generation of biofuels. The Deputy Mayor of Amsterdam, Lodewijk Asscher, said: "The city of Amsterdam is delighted with the progress of Avantium. Avantium ...
University of Massachusetts Medical School
Worcester, Massachusetts (ots/PRNewswire) - - ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate prophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among ...
Paris, France (ots/PRNewswire) - - EXCLAIM is the First International Study to Show That Extended Thromboprophylaxis Reduces VTE Risk in Acutely-ill Medical Patients With a Statistically Significant 44% Sanofi-aventis announced today the results of the EXCLAIM (EXtended CLinical prophylaxis in Acutely ...
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral ...
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, ...
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, ...
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral ...
European Society for Medical Oncology (ESMO)
PLEASE NOTE: FULL TEXT OF THE PRESS RELEASES AVAILABLE THROUGH WWW.ESMO.ORG/PRESSROOM upon registration PLEASE RESPECT INDIVIDUAL EMBARGO DATES/TIMES FOUND ON FULL PRESS RELEASES Lugano (ots) - HORMONE INHIBITOR PROMISING FOR HARD-TO-TREAT PROSTATE CANCER For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has assumed all marketing and distribution rights to BeneFIX(R) Coagulation Factor IX (Recombinant) in Europe. This transfer of responsibility follows the planned June 30, 2007 conclusion of a 10-year distribution rights agreement between Baxter Healthcare Corporation and Genetics Institute. ...
Midland, Michigan and Leverkusen, Germany (ots/PRNewswire) - - Dow Secures Application Expertise and Broader Cellulosics Offering for End-use Segments The Dow Chemical Company and the Bayer Group today announced the closing of Dow's acquisition of Wolff Walsrode. The purchase price of EUR 540 million (approximately USD 725 million) includes a cash component and the assumption of financial debt and pension ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today the enrolment of the last patient in its Phase 2b trial assessing ISA247 for the prevention of kidney graft rejection following transplantation. Of the 332 patients enrolled, 148 patients have already completed the required six months of treatment. The Company expects to have the last ...
Abbott Park, Illinois and South San Francisco, California (ots/PRNewswire) - Abbott (NYSE: ABT) and Genentech, Inc. (NYSE: DNA) have formed a collaboration for the global research, development and commercialization of two of Abbott's investigational anti-cancer compounds. The companies will work together on ...
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Updates Progress and Upcoming Milestones on its Insulin Program - TSX symbol: SBS SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical data supporting the ...
Chicago (ots/PRNewswire) - -- BYETTA offers added benefits of progressive weight loss in an analysis of the longest extension study to date -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced three-year, open-label study results that showed treatment with ...
Indianapolis (ots/PRNewswire) - - Daily dosing option is first prescription oral treatment to offer uninterrupted management of erectile dysfunction in select men Lilly (NYSE: LLY) announced today that the European Commission has granted marketing authorization for Cialis(R) (tadalafil)(1) 2.5 mg and 5 ...
Chicago (ots/PRNewswire) - -- When compared to insulin glargine, BYETTA offers the added benefits of progressive weight loss and lower risk of hypoglycaemia when used with metformin -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced study results comparing treatment with BYETTA(R)(exenatide) injection with insulin glargine in people with type 2 diabetes. Study ...
Basel, Switzerland (ots/PRNewswire) - An analysis of two large-scale Phase III maintenance studies on C.E.R.A. has highlighted that two high-risk patient populations - dialysis patients with diabetes and/or coronary artery disease - consistently and safely maintained their haemoglobin (Hb) levels at target levels ...
Chicago (ots/PRNewswire) - - Study also showed added benefits of reductions in cardiovascular risk factors and progressive weight loss - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study that showed BYETTA(R) (exenatide) injection in ...
Basel, Switzerland (ots/PRNewswire) - - New Study Reveals Potential for Improved use of Resources Whilst Maintaining High Quality Anaemia Management A new study has found that converting dialysis patients from more frequently administered erythropoiesis-stimulating agents (ESAs) to once-monthly C.E.R.A., ...